Non-invasive acute therapy heart infarction;Nicht-invasive akuttherapie des herzinfarktes

Internist

Volumn 42, Issue 5, 2001, Pages 665-681

  Tillmanns, H ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; AMIODARONE; ATENOLOL; CAPTOPRIL; CLOPIDOGREL; DILTIAZEM; ENALAPRILAT; EPTIFIBATIDE; GLYCERYL TRINITRATE; HEPARIN; HIRUDIN; HIRUGEN; HIRULOG; ISOSORBIDE MONONITRATE; LIDOCAINE; LISINOPRIL; MAGNESIUM; METOPROLOL; NIFEDIPINE; RETEPLASE; TICLOPIDINE; VERAPAMIL;

ACUTE HEART INFARCTION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; MAGNESIUM COMPOUNDS; META-ANALYSIS; MYOCARDIAL INFARCTION; NITROGLYCERIN; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; TACHYCARDIA, VENTRICULAR; THROMBOLYTIC THERAPY; UNITED STATES; VASODILATOR AGENTS; VENTRICULAR FIBRILLATION;

EID: 0035005692     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050808     Document Type: Review

References (66)

1. 1. ACE Inhibitor Myocardial Infarction Collaborative Group (1998) Indications for ACE inhibitors in the early treatment of acute myacardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 97: 2202-2212
2. 2. Antman EM, Giugliano RP, Gibson M et al. for the TIMI 14 Investigators (1999) Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolysis in myocardial infarction (TIMI) 14 Trial, Circulation 99: 2720-2732
3. 3. Baigent C, Collins R for the ISIS Collaborative Group (1993) ISIS-2: 4-year mortality follow-up of 17,187 patients after fibrinolytic and anti-platelet therapy in suspected acute myocardial infarction. Circulation 88 (Suppl): 1-291
4. 4. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, for the CLASSICS Investigators (2000) Double blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting - the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102: 624-629
5. 5. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL (1990) Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 66: 1412-1417
6. 6. Brener SJ, Barr LA, Burchenal JE et al. (1998) Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PICA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98: 734-41
7. 7. Coller BS, Scudder LE, Beer J et al. (1991) Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann NY Acad Sci 614: 193-213
8. 8. Collins R, MacMahon S, Flather M et al. (1996) Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 313: 652-659
9. 9. Collins R, Peto R, Baigent C, Sleight P (1997) Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 336: 847-860
10. 10. Danish Study Group on Verapamil in Myocardial Infarction (1984) Verapamil in acute myocardial infarction. Eur Heart J 5: 516-528
11. 11. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, Isea JE, Romero G (1998) Metabolic modulation of acute myocardial infarction.The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 98: 2227-2234
12. 12. EPIC Investigators (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 330: 956-961
13. 13. Furberg CD, Psaty BM, Meyer JV (1995) Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92: 1326-1331
14. 14. Gibson CM, Cannon CP, Murphy SA et al. (2000) Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101: 125-130
15. 15. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335: 775-782
16. 16. Goldbourt U, Behar S, Reicher-Reiss H, Zion M, Mandelzweig L, Kaplinsky E (1993) Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 153: 345-353
17. 17. Granger CB, Hirsh J, Califf RM et al. for the GUSTO-I Investigators (1996) Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Results from the GUSTO-I Trial. Circulation 93: 870-878
18. 18. Gruppo ltaliano per lo Studio della Sopravvivenza nell'infarto Miocardico (1994) GISSI-3: effects of Ilsinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 343: 1115-1122
19. 19. GUSTO Angiographic Investigators (1993) The effect of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329: 1615-1622
20. 20. GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329: 673-682
21. 21. Heintzen MP, Michel CJ, Schluter S et al. (1997) Interventionelle Therapie beim akuten Myokardinfarkt. Internist 38: 44-52
22. 22. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE (1996) Adjunctive drug therapy of acute myocardial infarction-evidence from clinical trials. N Engl J Med 335: 1660-1667
23. 23. Hjalmarson A (1984) Early intervention with a beta-blocking drug after acute myocardial infarction. Am J Cardiol 54: 11E-13E
24. 24. Hjalmarson A, Elmfeldt D, Herlitz J et al. (1981) Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 2: 823-827
25. 25. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM (1990) A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med 323: 1433-1437
26. 26. Huber K (1993) Die koronare Reokkiusionein ungelöstes Problem der Thrombolysetnerapie des akuten Herzinfarktes. Inn Med 48: 316-323
27. 27. International Collaborative Study Group (1984) Reduction of infarct size by the early use of intravenous timolol in acute myocardial infarction. Am J Cardiol 54: 14E-15E
28. 28. ISIS-1: First International Study Survival Collaborative Group (1986) Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 12: 57-66
29. 29. ISIS-2: Second International Study of Infarct Survival Collaborative Group (1988) Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarctions. Lancet 2: 349-360
30. 30. ISIS-4; Fourth International Study of Infarct Survival Collaborative Group (1995) ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345: 669-685
31. 31. Ito H, Okamura A, Iwakura K et al. (1996) Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 93: 1993-1999
32. 32. Jugdutt BI, Warnica JW (1988) Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 78: 906-919. Erratum in: Circulation (1989) 79: 1151
33. 33. Koster RW, Dunning AJ (1985) Intramuscular lidocaine for prevention of lethal arrhythmias in the prehospitalization phase of acute myocardial infarction. N Engl J Med 313: 1105-1110
34. 34. Lefkovits J, Ivanhoe RJ, Califf RM et al. (1996) Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol 77: 1045-1051
35. 35. Lemos JA de, Antman EM, Gibson CM et al. (2000) Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 101: 239-243
36. 36. Lie KI, Wellens HJJ, Downar E, Durrer D (1975) Observations on patients with primary ventricular fibrillation complicating acute myocardial infarction. Circulation 52: 755-759
37. 37. Lie KI, Wellens HJJ, van Capelle FJ, Durrer D (1974) Lidocaine in the prevention of primary ventricular fibrillation, A double-blind, randomized study of 212 consecutive patients. N Engl J Med 291: 1324-1326
38. 38. MacMahon S, Collins R, Peto R, Koster RW, Yusuf S (1988) Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. JAMA 260: 1910-1916
39. 39. Malmberg K, Ryden L, Efendic S et al. (1995) Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26: 57-65
40. 40. MIAMI Trial Research Group (1985) Metoprolol in acute myocardial infarction (MIAMI), A randomised placebo-controlled international trial. Eur Heart J 6: 199-226
41. 41. Montalescot G (2000) Six-month results of the ADMIRAL trial. Revascularization Conference, Paris. May 2000
42. 42. O'Connor CM, Meese R, Carney R et al. for the DUCCS Group, (1994) A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. J Am Coll Cardiol 23: 11-18
43. 43. Ohman EM, Kleiman NS, Gacioch G et al. (1997) Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial, IMPACT-AMI Investigators. Circulation 95: 846-854
44. 44. Rapold JH, de Bono D, Arnold AE, Arnout J, De Cock F, Collen D, Verstraete M (1992) Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group. Circulation 85: 928-934
45. 45. Roberts R (1989) beyond thrombolysis: clinical trials of adjunctive pharmacotherapies. In: Roberts R (ed) The age of reperfusion. McGraw Hill, New York, pp 1-12
46. 46. Roberts R, Rogers WJ, Mueller HS et al. (1991) Immediate versus deferred B-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 83: 422-437
47. 47. Ruan C, Destelle G, Wang Z, Wan H, He Y, Cheng D, Li P, Duffus M (1989) Ticlopidine in China: Comparative study on the effect of two dose levels on bleeding time and platelet function in healthy volunteers. Haemostasis 19: 94-99
48. 48. Ryan TJ, Anderson JL, Antman EM et al. (1996) ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 28: 1328-1428
49. 49. Ryan TJ, Antman EM, Brooks NH et al. (1999) 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 34: 890-911
50. 50. Schoemig A, Kastrati A, Dirschinger J et al. (2000) Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med 343: 385-391
51. 51. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group (2000) Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 101: 2788-2794
52. 52. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H (1992) Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction.Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327: 678-684
53. 53. Teo KK, Yusuf S (1993) Role of magnesium in reducing mortality in acute myocardial infarction. A review of the evidence. Drugs 46: 347-359
54. 54. Teo KK, Yusuf S, Furberg CD (1993) Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 270: 1589-1595
55. 55. Tillmanns H, Neumann FJ, Parekh N et al. (1990) Pharmacologic effects on coronary microvessels during myocardial ischemia. Eur Heart J 11 (Suppl): 10-15
56. 56. Tillmanns H, Steinhausen M, Leinberger H, Thederan H, Kübler W (1982) The effect of coronary vasodilators on the microcirculation of the ventricular myocardium. In: Tillmanns H, Kübler W, Zebe H (eds) Microcirculation of the heart. Theoretical and clinical problems. Springer, Berlin Heidelberg New York, pp 305-311
57. 57. Topol EJ (1998) Toward a new frontier in myocardial reperfusion therapy - Emerging platelet preeminence. Circulation 97: 211-218
58. 58. Van den Merkhof LF, Zijlstra F, Olsson H et al. (1999) Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol 33: 1528-1532
59. 59. Voss R (2000) Thrombozytenaggregationshemmer in der Kardiologie. Med Welt 11: 314-320
60. 60. Waldecker B, Waas W, Haberbosch W, Voss R, Heizmann H, Tillmanns H (1998) Long-term follow-up after direct percutaneous transluminal coronary angioplasty for acute myocardial infarction. J Am Coll Cardiol 32: 1320-1325
61. 61. Waidecker B, Waas W, Haberbosch W et al. (1999) Type 2 diabetes and acute myocardial infarction. Angiographic findings and results of an invasive therapeutic approach in type 2 diabetic versus nondiabetic patients. Diabetes Care 22: 1832-1838
62. 62. Weinberg B, Zipes D (1989) Strategies to manage the post-MI patient with ventricular arrhythmias. Clin Cardiol 12(Suppl): 86-90
63. 63. Wilcox RG, Hampton JR, Banks DC et al. (1986) Trial of early nifedipine in acute myocardial infarction: theTrent study. BMJ (Clin Res Ed) 293: 1204-1208
64. 64. Woods KL, Fletcher S, Roffe C, Haider Y (1992) Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 339: 1553-1558
65. 65. Yusuf S, Collins R, MacMahon S, Peto R (1988) Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1: 1088-1092
66. 66. Yusuf S, Peto R, Lewis J, Collins R (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335-371